Trial Profile

A phase 2b trial in COPD patients experiencing natural rhinovirus infections.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Sep 2025 According to Altesa BioSciences media release, Altesa BioSciences and bioMerieux announce collaboration for this study which will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE SPOTFIRE point-of-care diagnostics platform at U.S. sites.
13 Aug 2025 New trial record
24 Jul 2025 According to Altesa BioSciences media release, Based on results from Phase 2a, company is planning to conduct a multicenter, multinational, randomized controlled Phase 2b trial in COPD patients experiencing natural rhinovirus infections. The trial will begin in early 2026 and conclude and have topline results available in late 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com